Kiadis Pharma Continues to Provide Rhitol to Participating Physicians During Completion of Current Clinical Study

... AMSTERDAM November 19 /- Kiadis Pharma announced tod...Manja Bouman CEO Kiadis Pharma commented: We realised that the sites...The physicians interested in enabling new patients to receive treatmen...Rhitol is under development for patients with severe chronic steroidr...

AMSTERDAM, November 19 /PRNewswire/ -- Kiadis Pharma announced today
that it has agreed to provide Rhitol during a limited period of time to
requesting physicians participating in the ongoing phase I/II trial. The
Rhitol phase I/II trial is closed for enrolment to treat new patients and
is expected to complete at the end of this year. Kiadis Pharma anticipates
applying for and starting a phase III study in 2008.

Manja Bouman, CEO Kiadis Pharma commented: "We realised that the sites
participating in the ongoing phase II trial were left without treatment
alternatives following the announcement of the enrolment closure. The
interest these physicians show in using our product for new patients is
very encouraging and we are very pleased that we can support them by
providing Rhitol through special provisions, until the start of the phase
III clinical trial."

The physicians interested in enabling new patients to receive treatment
with Rhitol will obtain regulatory authorization from the appropriate
agency to allow for compassionate use of Rhitol.

Rhitol is under development for patients with severe chronic steroid
refractory Graft versus Host Disease (GvHD) who have exhausted other
treatment options. Chronic GvHD is a condition that can develop after
allogeneic bone marrow transplantation and resembles an autoimmune disease.
The immune cells from the donor graft cause GvHD by attacking the patient's
tissues and organs. There are two forms of GvHD: acute GvHD appears within
100 days after transplantation and chronic GvHD begins anytime after that
period. Immune-suppressant drugs, such as steroids, are generally used to
treat chronic GvHD. The disease can become a life-threatening condition
when standard treatment cannot control its progression as the patient
either does not respond to steroid treatment or develops severe side
effects due to their use. Extensive chronic GvHD affects multiple organs
and tissues and results in diminished quality of life for patients.

(Due to the length of this URL, it may be necessary to copy and paste
this hyperlink into your Internet browser's URL address field. Remove the
space if one exists.)

Certain statements in this announcement are forward-looking statements.
Such statements are based on current expectations and are subject to a
number of risks and uncertainties that could cause actual results or events
to differ materially from those expressed and implied by the
forward-looking statements

(Date:10/13/2017)... , ... October 13, 2017 , ... The American Board ... become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon ... beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon ...

(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the ... national organization of elder law and special needs planning attorneys. “Membership in ElderCounsel helps ... provides a forum to network with elder law attorneys nationwide,” said Somekh. , ...

(Date:10/13/2017)... ... 13, 2017 , ... Ellevate Network, the leading network for professional women, brought ... gender equality at their inaugural Summit in New York City in June. The event ... audience of over 3 million. To watch the Mobilize Women video, click here ...

(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...

(Date:10/2/2017)... The Rebound mobile app is poised to become ... tide of prescription drug addiction. The app empowers users to ... stepping down their dosage in a safe, controlled manner while ... the first 100,000 people to sign up will enjoy 3 ... ...

(Date:9/27/2017)... , Sept. 27, 2017 DarioHealth Corp. (NASDAQ: DRIO), a leading ... announced that its MyDario product is expected to appear on The Dr. ... The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show ... The segment ...